WO2002002788A2 - Procedes de production de vecteurs adenoviraux dependants d'un auxiliaire - Google Patents

Procedes de production de vecteurs adenoviraux dependants d'un auxiliaire Download PDF

Info

Publication number
WO2002002788A2
WO2002002788A2 PCT/US2001/015784 US0115784W WO0202788A2 WO 2002002788 A2 WO2002002788 A2 WO 2002002788A2 US 0115784 W US0115784 W US 0115784W WO 0202788 A2 WO0202788 A2 WO 0202788A2
Authority
WO
WIPO (PCT)
Prior art keywords
adenoviral
helper
adenovirus
derived
packaging
Prior art date
Application number
PCT/US2001/015784
Other languages
English (en)
Other versions
WO2002002788A3 (fr
Inventor
Donna Armentano
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Priority to AU2001271252A priority Critical patent/AU2001271252A1/en
Publication of WO2002002788A2 publication Critical patent/WO2002002788A2/fr
Publication of WO2002002788A3 publication Critical patent/WO2002002788A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Definitions

  • Adenoviral vectors for use in gene transfer to cells and especially in gene therapy applications commonly are derived from adenoviruses by deletion of the early region 1 (El) genes (Berkner, K.L., Curr. Top. Micro. Immunol. 158:39-66, 1992). Deletion of El genes renders such adenoviral vectors replication defective and significantly reduces expression of the remaining viral genes present within the vector. However, it is believed that the presence of the remaining viral genes in adenoviral vectors can be deleterious to the transfected cell for one or more of the following reasons: (1) stimulation of a cellular immune response directed against expressed viral proteins, (2) cytotoxicity of expressed viral proteins, and (3) replication of the vector genome leading to cell death.
  • El early region 1
  • adenoviral vectors which are adenoviral vectors derived from the genome of an adenovirus containing minimal cts-acting nucleotide sequences required for the replication and packaging of the vector genome and which can contain one or more transgenes (See, U.S. Patent No. 5,882,877 which covers pseudoadenoviral ("PAV”) or gutless vectors and methods for producing PAV, incorporated herein by reference).
  • PAV vectors which can accommodate up to 36 kb of foreign nucleic acid, are advantageous because the carrying capacity of the vector is optimized, while the potential for host immune responses to the vector or the generation of replication-competent viruses is reduced.
  • PAV vectors contain the 5' inverted terminal repeat (ITR) and the 3' ITR nucleotide sequences that contain the origin of replication, and the cw-acting nucleotide sequence required for packaging of the PAV genome, but do not comprise coding sequence for any adenoviral genes, and can accommodate one or more transgenes with appropriate regulatory elements.
  • ITR inverted terminal repeat
  • 3' ITR nucleotide sequences that contain the origin of replication
  • cw-acting nucleotide sequence required for packaging of the PAV genome but do not comprise coding sequence for any adenoviral genes, and can accommodate one or more transgenes with appropriate regulatory elements.
  • Adenoviral vectors including PAV, have been designed to take advantage of the desirable features of adenovirus which render it a suitable vehicle for nucleic acid transfer to recipient cells.
  • Adenovirus is a non-enveloped, nuclear DNA virus with a genome size of about 36 kb, which has been well-characterized through studies in classical genetics and molecular biology (Horwitz, M.S., "Adenoviridae and Their Replication," in Virology, 2nd edition, Fields et al., eds., Raven Press, New York, 1990).
  • the viral genes are classified into early (designated E1-E4) and late (designated L1-L5) transcriptional units, referring to the generation of two temporal classes of viral proteins.
  • the demarcation between these events is viral DNA replication.
  • the human adenoviruses are divided into numerous serotypes (approximately 47, numbered accordingly and classified into 6 subgroups: A, B, C, D, E and F), based upon properties including hemagglutination of red blood cells, oncogenicity, DNA base and protein amino acid compositions and homologies, and antigenic relationships.
  • Recombinant adenoviral vectors have several advantages for use as gene transfer vectors, including tropism for both dividing and non-dividing cells, minimal pathogenic potential, ability to replicate to high titer for preparation of vector stocks, and the potential to carry large inserts (Berkner, K.L., Curr. Top. Micro. Immunol. 158:39-66, 1992; Jolly, D., Cancer Gene Therapy 1:51-64, 1994).
  • the cloning capacity of an adenovirus vector is proportional to the size of the adenovirus genome present in the vector.
  • a cloning capacity of about 8 kb can be created from the deletion of certain regions of the virus genome dispensable for virus growth, e.g., E3, and the deletion of a genomic region such as El whose function may be restored in trans from 293 cells (Graham, F.L., J. Gen. Virol. 36:59-72, 1977) or A549 cells (Imler et al., Gene Therapy 3:75-84, 1996).
  • El-deleted vectors are rendered replication-defective.
  • the upper limit of vector DNA capacity for optimal carrying capacity is about 105%-108% of the length of the wild-type genome.
  • Further adenovirus genomic modifications are possible in vector design using cell lines which supply other viral gene products in trans, e.g., complementation of E2a (Zhou et al., J.
  • PAV vectors can accommodate up to 36 kb of foreign nucleic acid (U.S. Patent No. 5,882,877).
  • Transgenes that have been expressed to date by adenoviral vectors include inter alia p53 (Wills et al., Human Gene Therapy 5:1079-188, 1994); dystrophin
  • adenosine deaminase (Mitani et al., Human Gene Therapy 5:941-948, 1994); interleukin-2 (Haddada et al., Human Gene Therapy 4:703-711, 1993); al-antitrypsin (Jaffe et al., Nature Genetics 1 :372-378, 1992); thrombopoietin (Ohwada et al., Blood 88:778-784, 1996) and cytosine deaminase (Ohwada et al., Hum. Gene Ther., 7:1567-1576, 1996).
  • adenoviral vectors in gene transfer studies to date indicates that persistence of transgene expression in target cells and tissues is often transient. At least some of the limitation is due to the generation of a cellular immune response to the viral proteins which are expressed antigenically even from a replication-defective vector, triggering a pathological inflammatory response which may destroy or adversely affect the adeno virus-infected cells (Yang et al., J. Virol. 69:2004-2015, 1995; Yang et al., Proc. Natl. Acad. Sci. USA 91:4407-4411, 1994 Zsellenger et al., Hum Gene Ther. 6:457-467, 1995; Worgall et al., Hum. Gene Ther.
  • the adenovirus E3 gp 19K protein can complex with MHC Class I antigens and retain them in the endoplasmic reticulum, which prevents cell surface presentation and killing of infected cells by cytotoxic T-lymphocytes (CTLs) (Wold et al., Trends Microbiol.
  • CTLs cytotoxic T-lymphocytes
  • adenoviral vector-delivered transgenes may also be due to limitations imposed by the choice of promoter or transgene contained in the transcription unit (Guo et al., Gene Therapy 3:802-801, 1996; Tripathy et al., Nature Med.
  • adenoviral vectors for persistent transgene expression in target cells and tissues also involves the design of expression control elements, such as promoters, which confer persistent expression to an operably linked transgene.
  • Promoter elements which function independently of particular viral genes to confer persistent expression of a transgene, allow the use of vectors containing reduced viral genomes.
  • PAV vectors also contain a cz ' s-acting packaging sequence, normally located at the 5' end of the wild-type adenoviral genome.
  • the packaging sequence contains seven functional elements, identified as A repeats (Schmid et al., J. Virol 71:3375-3384, 1997).
  • helper virus can contain mutations in the packaging sequence of its genome which prevent packaging, or may contain an oversized adenoviral genome which cannot be packaged.
  • Novel helper viruses which facilitate the production of pseudoadeno viral vectors (PAV) by providing essential viral proteins in trans, but which are packaging defective due to the inclusion of binding sequences for repressor proteins that prevent utilization of the packaging signals in the helper virus genome have been disclosed in PC/US99/03483, filed February 17, 1999, incorporated herein by reference.
  • the PCT application also provides PAV producer cell lines expressing such repressor proteins and to methods for the production of PAV using such helper viruses and producer cell lines.
  • Lox sites are placed at positions flanking the Ad packaging sequences in the helper viral genome, which is produced in conventional 293 cells.
  • a Cre-expressing 293 cell is employed.
  • the helper genome can replicate and express viral genes so that the PAV genome can be packaged, but the packaging sequences are deleted from the helper through the action of the Cre protein.
  • helper-dependent adenoviral vectors such as PAV
  • PAV helper-dependent adenoviral vectors
  • the helper adenovirus contains packaging elements of a different serotype than that of the recombinant helper-dependent adenoviral vector. Because of the serotype differences, the packaging sequences present in the helper-dependent adenoviral vector have reduced ability to package the helper adenovirus.
  • helper adenovirus the ability of the helper adenovirus to become encapsidated, through recombination events, is significantly reduced, and significantly reduced amount of encapsidated helper adenovirus is produced.
  • the present invention provides methods and materials for the production of helper-dependent adenovirus, such as PAV, at high titers.
  • the invention comprises methods for producing high titers of helper-dependent adenovirus comprising co- transfecting a cell permissive for production of adenovirus with: (a) a helper-dependent adenoviral vector comprising inverted terminal repeats (ITRs) and packaging sequence derived from a first adenoviral serotype, and a transgene o ⁇ interest flanked by said ITRs; and (b) a chimeric packaging-deficient helper adenovirus which contains adenoviral genes derived from the first adenoviral serotype, and ITRs and packaging sequence derived from a second adenoviral serotype; and collecting the virions produced thereby.
  • ITRs inverted terminal repeats
  • the invention comprises methods for producing high titers of helper-dependent adenovirus comprising co-transfecting a cell permissive for production of adenovirus with: (a) a helper-dependent adenoviral vector comprising a ITRs and a packaging sequence derived from a first adenoviral serotype, preferably Ad2, and a transgene of interest flanked by said inverted terminal repeats (ITRs); and (b) a chimeric packaging-deficient helper adenovirus which contains adenoviral genes derived from the first adenoviral serotype, and a packaging sequence derived from a second adenoviral serotype; and collecting the virions produced thereby.
  • a helper-dependent adenoviral vector comprising a ITRs and a packaging sequence derived from a first adenoviral serotype, preferably Ad2, and a transgene of interest flanked by said inverted terminal repeats (ITRs)
  • the serotype origin of the ITRs flanking the chimeric packaging-deficient helper adenovirus may be derived from either the first adenoviral serotype or the second adenoviral serotype, but is preferably of the first adenoviral serotype, which is preferably Ad2.
  • the helper-dependent adenoviral vector is preferably a deleted adenoviral vector, such as a pseudoadenoviral vector, and its ITRs and packaging sequence are preferably derived from adenoviral subgroup C, more preferably from adenoviral serotypes 2, 5, 6 or 1, and most preferably from adenoviral serotypes 2 or 5.
  • the helper-dependent adenoviral vector may also be derived from other adenoviral subgroups.
  • the packaging sequence, and in certain cases, the ITRs, of the chimeric, packaging-deficient helper adenovirus are preferably derived from an adenoviral subgroup other than the subgroup from which are derived the ITRs and packaging sequence of the helper-dependent adenoviral vector, [for example, A, B, D, E or F when the helper-dependent adenoviral vector contains ITRs and packaging sequences derived from adenoviral subgroup C].
  • the chimeric, packaging- deficient helper adenoviruses preferably contain one or more adenoviral genes, which have been deleted from the helper-dependent adenoviral vector.
  • the adenoviral genes are of the same adenoviral subgroup or serotype as the ITRs and packaging sequence of the helper-dependent adenoviral vector.
  • the ITRs and packaging sequence of the helper-dependent adenoviral vector is derived from adenoviral subgroup C
  • the ITRs and packaging sequence of the chimeric, packaging-deficient helper adenovirus are preferably from adenoviral subgroup B or D, and most preferably from adenoviral serotype 7 or 17, respectively, while the adenoviral genes of the helper adenovirus are derived from the subgroup C.
  • the adenoviral genes of the chimeric, packaging-deficient helper adenovirus is preferably of the same subgroup, and the ITRs and packaging sequence of the chimeric, packaging-deficient helper adenovirus is preferably selected from a second adenoviral subgroup which is distinct from that of the helper-dependent adenoviral vector.
  • the helper-dependent adenoviral vector comprises ITRs and packaging sequence derived from subgroup B
  • the chimeric, packaging-deficient helper adenovirus preferably comprises ITRs and packaging sequence from a subgroup other than B [e.g., A, C, D, E or F].
  • the helper adenovirus preferably comprises one or more adenoviral genes of the same subgroup as the helper-dependent adenoviral vector [e.g., subgroup B]. These adenoviral genes will provide the critical elements that are missing from the helper-dependent adenoviral vector, and allow the adenoviral vector to replicate and be encapsulated.
  • kits for producing high titers of helper-dependent adenovirus comprising co-transfecting a cell permissive for production of adenovirus with: (a) a helper-dependent adenoviral vector comprising inverted terminal repeats (ITRs) and packaging sequence [ ⁇ ] derived from a first adenoviral serotype from subgroup C, a transgene of interest flanked by said ITRs; and (b) a chimeric helper adenovirus with packaging sequence [ ⁇ ] derived from adenoviral subgroup B or D, and adenoviral genes derived from the first adenoviral serotype; and then collecting the virions produced from the co-transfected cell.
  • ITRs inverted terminal repeats
  • the helper-dependent adenoviral vector is preferably a deleted adenoviral vector, such as a pseudoadenoviral vector.
  • the adenoviral serotype of the helper-dependent adenoviral vector is preferably adenovirus 2 or 5.
  • the ITRs of the chimeric helper adenovirus is preferably derived from the first adenoviral serotype or the second adenoviral serotype.
  • the invention comprises chimeric, packaging-deficient helper adenoviruses useful for the propagation of helper-dependent adenoviral vectors of a first adenoviral serotype.
  • the chimeric helper adenovirus comprises adenoviral genes derived from a first adenoviral serotype, preferably of subgroup C, and packaging sequence [ ⁇ ] derived from a second adenoviral serotype, preferably of subgroup A, B, D or E, more preferably subgroup B or D.
  • the ITRs of the chimeric helper adenovirus is preferably derived from the first adenoviral serotype or the second adenoviral serotype.
  • the chimeric, packaging- deficient helper adenovirus comprises adenoviral genes derived from an adenoviral serotype selected from the group consisting of serotypes 2 and 5, and ITRs and packaging sequence derived from an adenoviral serotype selected from the group consisting of serotypes 7 and 17.
  • the present invention is further directed to methods for production of helper-dependent adenoviral vectors.
  • helper-dependent adenoviral vectors include pseudoadenoviral ("PAV") or "gutless" adenoviral vectors.
  • Helper-dependent adenoviral vectors are being developed for a variety of gene therapy applications.
  • the vectors retain the cis elements required for DNA replication and packaging such as the inverted terminal repeats (ITRs) and packaging signal () but may be devoid of all other adenoviral coding regions, which may be replaced by an expression cassette of interest and "stuffer" sequences.
  • the viral gene products required for virus growth and encapsidation must therefore be supplied in trans by a helper virus in order to produce PAV.
  • helper-dependent virus and the helper virus are derived from the same adenovirus serotype and PAV is co-propagated with helper virus which leads to the production of both vectors within the cell.
  • Several strategies have been employed to reduce the presence of helper in virus preparations.
  • One strategy is based on constructing PAV and helper with different genomic lengths such that PAV and helper virus particles can be separated by CsCl density gradient centrifugation. Another is based on modifying the packaging signals within PAV and/or the helper virus such that the helper becomes less efficiently encapsidated.
  • a third strategy, which is the most efficient, is based on Cre/Lox mediated excision of the packaging signal from the helper in the producer cell resulting in 100-1000 fold reduction of encapsidation. All these strategies yield some helper virus contamination in the PAV preparation and tend to generate replication competent adenovirus.
  • the present invention comprises methods for producing high titers of helper-dependent adenovirus comprising co-transfecting a cell permissive for production of adenovirus with: (1) a helper-dependent adenoviral vector comprising inverted terminal repeats (ITRs) and packaging sequence [ ⁇ ] derived from a first adenoviral subgroup, and a transgene of interest flanked by said ITRs; and (2) a packaging-deficient helper adenovirus which contains adenoviral genes derived from a first adenoviral subgroup, but packaging sequence [ ⁇ ] from a second adenoviral subgroup; and collecting virions produced thereby.
  • the ITRs of the helper adenovirus may preferably be derived from either the first or second adenoviral subgroup.
  • the packaging sequence [ ⁇ ] of the helper adenoviral vector is preferably selected from the group consisting of subgroup B and subgroup D, more preferably selected serotype 7 and serotype 17, respectively.
  • the adenoviral genes in the helper are preferably selected from subgroup C.
  • the packaging-deficient helper virus may contain mutations in the packaging sequence of its genome which prevent packaging, or may contain an oversized adenoviral genome which cannot be packaged. Alternatively, packaging of the helper virus may reduced through the use of the Cre/Lox system or other recombinase.
  • the ITRs of the helper adenovirus may preferably be derived from either the first or second adenoviral subgroup.
  • the ITRs and packaging sequence [ ⁇ ] of the helper-dependent adenoviral vector are preferably derived from adenovirus subgroup C, more preferably derived from the adenovirus serotype 2 or serotype 5.
  • the present invention comprises methods for producing high titers of helper-dependent adenovirus comprising co-transfecting a cell permissive for production of adenovirus with both (1) a helper-dependent adenoviral vector comprising ITRs and packaging sequence [ ⁇ ] derived from a first adenoviral serotype, and a transgene flanked by said ITRs; and (2) a chimeric helper adenoviral vector comprising packaging sequence [ ⁇ ] derived from a second adenoviral serotype, adenoviral genes derived from the first adenoviral serotype, and inverted terminal repeats (ITRs) derived from either the first or second adenoviral serotype; and then collecting virions produced
  • the helper-dependent adenoviral vector is a partially or fully deleted adenoviral vector. In the most preferred embodiment, the helper-dependent adenoviral vector is a fully deleted pseudoadenoviral vector.
  • the helper-dependent adenoviral vector preferably comprises ITRs and packaging sequences [ ⁇ ] derived from adenoviral subgroups C, and more preferably the ITRs and packaging sequences [ ⁇ ] are derived from adenoviral serotypes 2, 5, 6 or 1.
  • the helper adenovirus useful in the methods of the present invention is preferably a chimeric adenovirus which contains a full complement of the adenoviral genome.
  • the helper adenovirus may be a chimeric adenovirus which contains adenoviral genes to complement the adenoviral functions which have been deleted from the helper-dependent adenoviral vectors which the helper adenovirus is designed to support.
  • one or more of the adenoviral genes is preferably derived from the same adenoviral subgroup as the helper-dependent adenoviral vector it is designed to support, while the packaging sequence of the helper adenovirus is derived from a second subgroup.
  • the ITRs of the helper adenovirus are preferably derived from either the first adenoviral subgroup or the second adenoviral subgroup.
  • the adenovirus El genes in the helper are preferably from adenovirus subgroup C, and is more preferably of adenoviral serotype 2, 5, 6 or 1, most preferably derived from adenoviral serotype 2 or 5.
  • the helper adenovirus may be packaging-deficient.
  • the helper adenovirus can contain mutations in the packaging sequence of its genome which prevent packaging, or may contain an oversized adenoviral genome which cannot be packaged.
  • helper viruses useful in the present invention may be packaging defective due to the inclusion of binding sequences for repressor proteins that prevent utilization of the packaging signals in the helper virus genome, or in which packaging of the helper is reduced through the use of the Cre/Lox or other recombinase system.
  • recombinase systems include Flp recombinase (Senecoff et al., 1985, Proc. Natl. Acad. Sci. USA 82:7270- 7274; Buchholz et al., 1998, Nature Biotechnol.
  • a recombinase (R) encoded by the pSRl plasmid of the yeast Zygosaccharomyces rouxii has similar function to FLP (Kilby et al., 1993, TIG 9:413-421).
  • the "R" recombinase and its recognition sequences may also facilitate the binding and recombination referred to herein.
  • the disclosure of all of these publications is hereby incorporated herein by reference.
  • the present invention comprises helper-dependent adenoviral vectors.
  • the helper-dependent adenoviral vectors of the present invention preferably comprise inverted terminal repeats (ITRs) and packaging sequence, and a transgene of interest flanked by said ITRs.
  • the helper-dependent adenoviral vector is a pseudoadenoviral vector, which contains no coding sequences for adenoviral genes.
  • the ITRs and packaging sequence are derived from an adenoviral serotype selected from the group consisting of adenovirus subgroup C, more preferably from adenovirus serotype 2, 5, 6 or 1, more preferably from adenovirus serotypes 2 or 5.
  • the present invention comprises a chimeric helper adenovirus which contains a packaging sequence [ ⁇ ] derived from a different adenoviral serotype subgroup than that of the adenoviral genome of the helper adenovirus, said packaging sequence being flanked by target sites of recombination such as lox sites, for use with the Cre/lox system.
  • a packaging sequence [ ⁇ ] derived from a different adenoviral serotype subgroup than that of the adenoviral genome of the helper adenovirus
  • the packaging sequence being flanked by target sites of recombination such as lox sites, for use with the Cre/lox system.
  • Sequence ID NO: 1 is a nucleotide sequence from the ITR and ⁇ sequences of Ad serotype 2.
  • Sequence ID NO:2 is a nucleotide sequence from the ITR and ⁇ sequences of Ad serotype 4.
  • Sequence ID NO: 3 is a nucleotide sequence from the ITR and ⁇ sequences of Ad serotype 7.
  • Sequence ID NO:4 is a nucleotide sequence from the ITR and ⁇ sequences of Ad serotype 12.
  • Sequence ID NO: 5 is a nucleotide sequence from the ITR and ⁇ sequences of Ad serotype 17.
  • Figure 1 illustrates the alignment of ITR and ⁇ sequences from Ad2 (subgroup C) with Adl2 (subgroup A).
  • Figure 2 illustrates the alignment of ITR and ⁇ sequences from Ad7 (subgroup B) with
  • Ad2 (subgroup C).
  • Figure 3 illustrates the alignment of ITR and ⁇ sequences from Adl7 (subgroup D) with Ad2 (subgroup C).
  • Figure 4 illustrates the alignment of ITR and ⁇ sequences from Ad4 (subgroup E) with Ad2 (subgroup C).
  • Figure 5 illustrates constructs generated containing either the Ad7 or Adl7 ITRs +/- ⁇ sequences linked to ad Ad2 genome in which the El region was deleted and replaced with a ⁇ - galactosidase expression cassette.
  • Ad2-p7 and Ad2-7 contain the ITRs +/- ⁇ sequences from Ad7, respectively and Ad2-pl7 and Ad2-17 contain the ITRs +/- ⁇ sequences from Adl7, respectively.
  • Ad2-EGFP is a positive control virus that is entirely derived from Ad2 in which the El region was deleted and replaced with a green fluorescent protein expression cassette.
  • Panel A illustrates various assays that were conducted for analysis of viral replication and packaging.
  • Plasmids were digested with SnaBI and the DNAs were transfected into parallel cultures of 293 cells. The ability of the constructs to replicate over a time course of 0 to 96 hours post-transfection was monitored by Southern analysis, illustrated in Figure 6, panel B Figure 7 shows the results of plaque assays. For both the Ad2-p7 and Ad2-pl7 constructs virus titer is reduced more that one order of magnitude compared to positive control, pAd2EGFP. In addition, the appearance of plaques is delayed by 3-4 days.
  • Figure 8 illustrates the yield of Ad2-p7 is increased by more that three orders of magnitude when cultures are co-infected with wild type Ad7 virus while the yield remains unchanged in cultures co-infected with wild type Ad2. This suggests that the wild type Ad7 virus can supply a factor(s) in trans that rescues the Ad2-p7 virus. Similar results were observed with Ad2-pl7.
  • Figure 9 illustrates the relative titers of vector [Ad2- ⁇ -gal4] and chimeric helper adenovirus [Ad2- ⁇ 17] with packaging sequence derived from Adl7.
  • Figure 10 shows the alignment of Ad2 and Adl7 packaging sequences. Sequences shown in bold are the A repeats in the packaging signal. Sequences underlined are enhancer regions.
  • PAV helper dependent adenoviral vector
  • a recombination event in the ⁇ region would lead to loss of the ability to remove ⁇ from the helper.
  • the ⁇ regions share approximately 74% homology and since Adl7 ⁇ functions in the context of an Ad2 based vector, this might be incorporated into helper vectors as one strategy to reduce recombination between helper and PAV. . - ⁇
  • Adenovirus DNA replication is well understood and both viral and cellular components that are required for this process have been identified for different adenovirus subgroups.
  • FIG. 1 Adenoviral DNA encapsidation is less understood.
  • Encapsidation or packaging signal sequences ( ⁇ ) have been identified for subgroup C viruses as well as cellular factors that bind to these sequences. Not all of the identified subgroup C packaging signal elements are conserved in viruses from other subgroups and the overall homology of the ITR and packaging signal region of subgroup C viruses with other subgroup members ranges from 60-68%.
  • Figures 1-4 show the alignment of ITR and ⁇ sequences from Ad2 (subgroup C) with Ad 12 (subgroup A), Ad7 (subgroup B), Adl7 (subgroup D) and Ad4 (subgroup E), respectively.
  • the invention is based on the observation that viruses from different subgroups do not efficiently cross-package each other due to differences in the required packaging signal sequences (both known and unknown) and differences in viral proteins that direct subgroup specific packaging.
  • the invention is directed to novel helper adenoviruses for the production of helper-dependent adenoviral vectors, such as PAV.
  • a helper vector could contain the packaging signal +/- the ITRs from one subgroup but contain the remainder of the genome of the subgroup from which PAV is derived. This would require a complementing cell line that supplies the packaging factor(s) in trans for packaging the helper.
  • the helper can then be used in a non- complementing cell line to generate PAV.
  • Cell lines useful in the methods of the present invention include those cell lines which are permissive for adenoviral replication and packaging, including, but not limited to human 293 embryonic kidney cells, A549 embryonic kidney cells, and PerC6 embryonic retinal cells.
  • the chimeric helper adenovirus of the present invention comprise packaging sequences from a serotype other than adenovirus 2 serotype.
  • the ITRs of the chimeric helper adenovirus may preferably be derived from a serotype other than adenovirus 2 serotype.
  • the invention is also directed at generating helper vectors that have a reduced potential for recombination with PAV.
  • ITRs on the helper and PAV can be derived from different subgroups to reduce the potential for recombination. As shown in figures 1-4 the homologies of ITRs between subgroups ranges from 60-80%.
  • FIG. 5 depicts constructs that were generated containing either the Ad7 or Adl7 ITRs +/- ⁇ sequences linked to an Ad2 genome in which the El region was deleted and replaced with a ⁇ -galactosidase expression cassette.
  • Ad2-p7 and Ad2-7 contain the ITRs +/- ⁇ sequences from Ad7, respectively and Ad2-pl7 and Ad2-17 contain the ITRs +/- ⁇ sequences from Adl7, respectively.
  • Ad2-EGFP is a positive control virus that is entirely derived from Ad2 in which the El region was deleted and replaced with a green fluorescent protein expression cassette. All vectors contain a 2.9kb deletion in the E3 region. The constructs were generated in plasmid form from which the chimeric genomes could be excised by digestion with restriction endonuclease SnaBI.
  • FIG. 6 panel A schematically depicts the various assays that were done for analysis of viral replication and packaging. Plasmids were digested with SnaBI and the DNAs were transfected into parallel cultures of 293 cells. The ability of the constructs to replicate over a time course of 0 to 96 hours post-transfection was monitored by Southern analysis, shown in Figure 6, panel B. DNA replication of Ad2-p7 and Ad2-7 appear to exhibit similar kinetics to the positive control vector, Ad2-EGFP, indicating that the Ad2 (subgroup C) replication machinery can replicate DNA containing ITRs derived from Ad7 (subgroup B). DNA replication of Ad2-pl7 and Ad2- 17 appears to be delayed and is not detected until 48 hours post transfection.
  • the DNAs accumulate to similar amounts as Ad2-EGFP indicating that although delayed, the Ad2 replication machinery can replicate DNA containing ITRs derived from Adl7 (subgroup D. Constructs that do not contain a packaging signal appear to replicate with similar kinetics to their counterparts that do suggesting that the packaging signal is dispensable for DNA replication.
  • the released virus was titered by hexon staining to measure total virus yield and by X-gal staining to measure chimeric virus yield.
  • the yield of Ad2-p7 is increased by more that three orders of magnitude when cultures are co-infected with wild type Ad7 virus while the yield remains unchanged in cultures co-infected with wild type Ad2. This suggests that the wild type Ad7 virus can supply a factor(s) in trans that rescues the Ad2-p7 virus.
  • a similar result is observed for Ad2-pl7.
  • the yield of this virus is also increased by more than three orders of magnitude when cultures are co-infected with wild type Ad 17 whereas the yield remains unchanged in cultures co-infected with wild type Ad2. This suggests that wild type Adl7 virus can supply a factor(s) in trans that rescues the Ad2-pl7 virus.
  • Ad2- ⁇ l7 shown in panel A, is Ad2-based but contains ⁇ from Ad 17 and was generated by transfection into 293 cells. This virus was expanded in PerC.6 cells and analyzed for virus yield in the presence or absence of wild type Adl7. As shown, the titer of Ad2- ⁇ l7, unlike Ad2-pl7 ( Figure 9), does not increase when it is grown in the presence of wild type Adl7. This suggests that supplying Adl7 functions in trans does not increase titer and that elements involved in subgroup specific packaging lie outside of the ⁇ region.
  • Ad2- ⁇ l7 compared to Ad2//3gal-4 which is completely Ad2-based is modestly affected suggesting that the Adl7 ⁇ can function in place of Ad2 ⁇ , but less efficiently.
  • the titer of Ad2- ⁇ l7 is not affected when grown in the presence of Ad2//3gal-4, further supporting the interchangeability of the ⁇ regions.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés et des matières permettant la production d'adénovirus dépendant d'un auxiliaire, tels que PAV, à des titres élevés. Dans un mode de réalisation, l'invention concerne des procédés de production de titres élevés d'adénovirus dépendants d'un auxiliaire, consistant à co-transfecter une cellule permettant la production d'adénovirus au moyen a) d'un vecteur adénoviral dépendant d'un auxiliaire contenant des séquences terminales répétées et inversées (ITR) et une séquence d'encapsidation dérivée d'un premier sérotype adénoviral, et un transgène d'intérêt flanqué desdites ITR, b) d'un adénovirus auxiliaire chimère à encapsidation déficiente contenant des gènes adénoviraux dérivés du premier sérotype adénoviral, une séquence d'encapsidation dérivée d'un second sérotype adénoviral, et des ITR dérivées du premier ou du second sérotype adénoviral. Le procédé consiste ensuite à collecter les virions ainsi produits.
PCT/US2001/015784 2000-06-29 2001-05-16 Procedes de production de vecteurs adenoviraux dependants d'un auxiliaire WO2002002788A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001271252A AU2001271252A1 (en) 2000-06-29 2001-05-16 Methods for helper-dependent adenoviral vector production

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21504700P 2000-06-29 2000-06-29
US60/215,047 2000-06-29
US25974801P 2001-01-04 2001-01-04
US60/259,748 2001-01-04

Publications (2)

Publication Number Publication Date
WO2002002788A2 true WO2002002788A2 (fr) 2002-01-10
WO2002002788A3 WO2002002788A3 (fr) 2003-01-03

Family

ID=26909633

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/015784 WO2002002788A2 (fr) 2000-06-29 2001-05-16 Procedes de production de vecteurs adenoviraux dependants d'un auxiliaire

Country Status (3)

Country Link
US (1) US20020081707A1 (fr)
AU (1) AU2001271252A1 (fr)
WO (1) WO2002002788A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013597A2 (fr) * 1994-10-28 1996-05-09 The Trustees Of The University Of Pennsylvania Adenovirus recombine et ses procedes d'utilisation
WO1999041400A1 (fr) * 1998-02-17 1999-08-19 Genzyme Corporation Procedes de fabrication de vecteurs pseudo-adenoviraux
WO1999061638A1 (fr) * 1998-05-27 1999-12-02 Transgene S.A. Vecteurs adenoviraux chimeres
WO2000046360A1 (fr) * 1999-02-04 2000-08-10 Merck & Co., Inc. Amelioration du systeme vecteur dependant d'un assistant-dependant pour la therapie genique
WO2001053504A1 (fr) * 2000-01-21 2001-07-26 University Of Michigan Medical School Vecteurs adenovirus deficients pour la replication

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013597A2 (fr) * 1994-10-28 1996-05-09 The Trustees Of The University Of Pennsylvania Adenovirus recombine et ses procedes d'utilisation
WO1999041400A1 (fr) * 1998-02-17 1999-08-19 Genzyme Corporation Procedes de fabrication de vecteurs pseudo-adenoviraux
WO1999061638A1 (fr) * 1998-05-27 1999-12-02 Transgene S.A. Vecteurs adenoviraux chimeres
WO2000046360A1 (fr) * 1999-02-04 2000-08-10 Merck & Co., Inc. Amelioration du systeme vecteur dependant d'un assistant-dependant pour la therapie genique
WO2001053504A1 (fr) * 2000-01-21 2001-07-26 University Of Michigan Medical School Vecteurs adenovirus deficients pour la replication

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PARKS R J ET AL: "A HELPER.DEPENDENT ADENOVIRUS VECTOR SYSTEM: REMOVAL OF HELPER VIRUS BY CRE-MEDIATED EXCISION OF THE VIRAL PACKAGING SIGNAL" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 24, 26 November 1996 (1996-11-26), pages 13565-13570, XP000617948 ISSN: 0027-8424 cited in the application *
SANDIG V ET AL: "OPTIMIZATION OF THE HELPER-DEPENDENT ADENOVIRUS SYSTEM FOR PRODUCTION AND POTENCY IN VIVO" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 3, 1 February 2000 (2000-02-01), pages 1002-1007, XP000985990 ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2002002788A3 (fr) 2003-01-03
US20020081707A1 (en) 2002-06-27
AU2001271252A1 (en) 2002-01-14

Similar Documents

Publication Publication Date Title
US5922576A (en) Simplified system for generating recombinant adenoviruses
Bett et al. Packaging capacity and stability of human adenovirus type 5 vectors
AU763187B2 (en) Generation of packaging system for human recombinant adenoviral vectors
US7001596B1 (en) Oncolytic adenovirus
US6228646B1 (en) Helper-free, totally defective adenovirus for gene therapy
EP0988389B1 (fr) Procede de production de vecteurs adenoviraux n'appartenant pas au groupe c
US5981225A (en) Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
PT1349926E (pt) Linhas celulares de complementação
Gao et al. A cell line for high-yield production of E1-deleted adenovirus vectors without the emergence of replication-competent virus
Sirena et al. The nucleotide sequence and a first generation gene transfer vector of species B human adenovirus serotype 3
AU752284B2 (en) Methods for pseudoadenoviral vector production
EP1691765A2 (fr) Adenovirus a activite oncolytique
US20020081707A1 (en) Methods for helper-dependent adenoviral vector production
US6541245B1 (en) Adenoviral helper vectors
WO1999036557A1 (fr) Nouveaux elements de promoteur assurant l'expression genique durable
WO2001021824A1 (fr) Vecteurs auxiliaires et lignees cellulaires de production de vecteurs pseudoadenoviraux
EP1083229A1 (fr) Vecteurs adénovirales modifiés pour la thérapie génique
CA2384439A1 (fr) Vecteurs adenoviraux modifies a utiliser en therapie genique
US7585498B2 (en) Regulation of adenovirus DNA packaging by IPTG
EP1083228A1 (fr) Vecteurs adénovirales modifiés pour la thérapie génique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP